November 21, 2025 16:30 ET | Source: Olema Oncology SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”,…
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase…
The Medidata Data Experience offering will enable the National Cancer Institute Lead Protocol Organizations to expedite the development of life-saving…
Canadian Cancer Society report highlights global progress on key tobacco control measures TORONTO, Nov. 18, 2025 /PRNewswire/ -- An international…
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel…
BOSTON and SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine,…
Updated cancer treatment guidelines reflect significant progress in cancer care delivery through ongoing collaborative efforts to strengthen oncology resources across…
BENGALURU, India, Nov. 4, 2025 /PRNewswire/ -- The streets of Bengaluru turned pink on Saturday morning, as over 30 women…
Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible…
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and…